SCI Abstract

search
+
Body mass index as a predictor of MS activity and progression among participants in BENEFIT
Body mass index as a predictor of MS activity and progression among participants in BENEFIT
Background:There is a lack of studies on the association between obesity and conversion from a clinically isolated syndrom...
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
Background:The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is ...
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO
1. Barun, B, Gabelic, T, Adamec, I, et al. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 ...
Response to “Frailty in multiple sclerosis: A closer look at the deficit accumulation framework”
Response to “Frailty in multiple sclerosis: A closer look at the deficit accumulation framework”
Daniele Belvisi1, 2*, Marco Canevelli1, 3*, Girolama Alessandra Marfia2, 4, Elisabetta Ferraro5, Diego Centonze2, 4, ...
Gene–environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution
Gene–environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution
Background:We previously reported a relationship between air pollutants and increased risk of pediatric-onset multiple scl...
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – Yes
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – Yes
1. Montalban, X, Hauser, SL, Kappos, L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Eng...
Assessing diagnosis disclosure and concealment in multiple sclerosis: Building a framework for moving forward
Assessing diagnosis disclosure and concealment in multiple sclerosis: Building a framework for moving forward
Access to society journal content varies across our titles. If you have access to a journal via a society or association ...
Diagnosis concealment is associated with psychosocial outcomes in persons with multiple sclerosis
Diagnosis concealment is associated with psychosocial outcomes in persons with multiple sclerosis
Persons with multiple sclerosis (pwMS) frequently conceal their diagnosis, fearing professional and personal repercussions...
The frequency and characteristics of multiple sclerosis misdiagnosis in Latin America: A referral center study in Buenos Aires, Argentina
The frequency and characteristics of multiple sclerosis misdiagnosis in Latin America: A referral center study in Buenos Aires, Argentina
Objective:Most contemporary data concerning the frequency and causes of multiple sclerosis (MS) misdiagnosis are from Nort...
Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS
Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS
Background:Health-related quality of life (HRQOL) outcomes are often included as secondary outcomes in clinical trials in ...
Absence of attack-independent neuroaxonal injury in MOG antibody-associated disease: Longitudinal assessment of serum neurofilament light chain
Absence of attack-independent neuroaxonal injury in MOG antibody-associated disease: Longitudinal assessment of serum neurofilament light chain
To evaluate the occurrence of attack-independent neuroaxonal and astrocytic damage in myelin oligodendrocyte glycoprotein ...
The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study
The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study
Background:Cerebrospinal fluid (CSF) free light chains (FLCs) can be an alternative assay to oligoclonal bands (OCBs) in i...
Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review
Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review
Background:Cognitive dysfunction as a predictor of clinical progression and mortality in multiple sclerosis (MS) is still ...
Disease-modifying drugs for multiple sclerosis and subsequent health service use
Disease-modifying drugs for multiple sclerosis and subsequent health service use
Objective:We assessed the relationship between the multiple sclerosis (MS) disease-modifying drugs (DMDs) and healthcare u...
Extended dosing of monoclonal antibodies in multiple sclerosis
Extended dosing of monoclonal antibodies in multiple sclerosis
Over the past two decades, treatment options for patients with multiple sclerosis (MS) have increased exponentially. In th...
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica
Introduction:Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based ...
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
In women with very active multiple sclerosis (MS), natalizumab can be continued during pregnancy to prevent rebound diseas...
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
1. Ocrevus United States . New drug application, March 2017, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/76105...
MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination
MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination
This case report describes a 59-year-old man with myelin oligodendrocyte glycoprotein (MOG)-positive longitudinal extensiv...
Frailty in multiple sclerosis: A closer look at the deficit accumulation framework
Frailty in multiple sclerosis: A closer look at the deficit accumulation framework
Tobia Zanotto1, Sharon G Lynch2, Jeffrey M Hausdorff3, 4, 5, 6, Jacob J Sosnoff11Department of Physical Therapy and Re...
Computational basis of decision-making impairment in multiple sclerosis
Computational basis of decision-making impairment in multiple sclerosis
Background:Multiple sclerosis (MS) is commonly associated with decision-making, neurocognitive impairments, and mood and m...
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – Commentary
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – Commentary
Access to society journal content varies across our titles. If you have access to a journal via a society or association ...
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – No
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – No
1. Brown, JWL, Coles, A, Horakova, D, et al. Association of initial disease-modifying therapy with later conversion to sec...
LACTRIMS 2021
LACTRIMS 2021
Access to society journal content varies across our titles. If you have access to a journal via a society or association ...
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Does preexisting or treatment-emergent autoimmunity increase the risk of subsequent autoimmune disease in individuals with...
Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD
Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD
In a large acute myelitis cohort, we aimed to determine whether brighter spotty lesions (BSLs)—using the refined terminolo...
Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients
Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients
Background:Active (new/enlarging) T2 lesion counts are routinely used in the clinical management of multiple sclerosis. Th...
Impact of comorbid post traumatic stress disorder on multiple sclerosis in military veterans: A population-based cohort study
Impact of comorbid post traumatic stress disorder on multiple sclerosis in military veterans: A population-based cohort study
Background:Very little is known regarding the impact of post traumatic stress disorder (PTSD) on the course of multiple sc...
Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal
Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal
Background:Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals ...
Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis
Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis
Objective:To evaluate whether oral contraceptive (OC) use is associated with the risk of a second attack and disability ac...
Load More
format_indent_increase